Elevation Oncology Balance Sheet Health
Financial Health criteria checks 5/6
Elevation Oncology has a total shareholder equity of $69.4M and total debt of $31.0M, which brings its debt-to-equity ratio to 44.7%. Its total assets and total liabilities are $106.3M and $36.9M respectively.
Key information
44.7%
Debt to equity ratio
US$31.02m
Debt
| Interest coverage ratio | n/a |
| Cash | US$103.07m |
| Equity | US$69.36m |
| Total liabilities | US$36.95m |
| Total assets | US$106.30m |
Recent financial health updates
We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10
We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Recent updates
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
May 03Elevation Oncology: Rising On News, But Not The Time To Buy
Jan 17Elevation Oncology GAAP EPS of -$0.86 misses by $0.07
Aug 04Elevation Oncology secured $50M loan facility with K2 HealthVentures
Jul 28We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely
May 10We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate
Jan 25Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth
Sep 25Financial Position Analysis
Short Term Liabilities: ELEV's short term assets ($105.3M) exceed its short term liabilities ($5.9M).
Long Term Liabilities: ELEV's short term assets ($105.3M) exceed its long term liabilities ($31.0M).
Debt to Equity History and Analysis
Debt Level: ELEV has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ELEV's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELEV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELEV has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 26.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:59 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elevation Oncology, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Michael King | H.C. Wainwright & Co. |
| Silvan Tuerkcan | JMP Securities |